NCT02220153已完成1 期
A Subject-Blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of UCB7665 in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- UCB Celltech
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Incidence of adverse events during the study
研究概览
简要总结
This study is designed to evaluate the safety and tolerability of single ascending doses of UCB7665 administered by intravenous or subcutaneous infusion in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female volunteers of non-childbearing potential who gave their consent to the written informed consent form
- •Healthy volunteers in the age between 18 and 64 years old with normal weight as determined by a body mass index (BMI) between 18 and 30 kg/m^2, with a body weight of at least 50 kg for male subjects or 45 kg for female subjects
- •Subjects has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes rest
- •Subject has clinical laboratory test results within the reference ranges of the testing laboratory or test results that are outside the specified ranges and that are deemed as clinically non-significant
- •Subject's electrocardiogram (ECG) is considered "normal" or "abnormal" but clinically non-significant
排除标准
- •Subject has had significant blood loss, or has donated blood in excess of 400 mL of blood or blood products within 90 days before Day -2, or plans to donate blood during the clinical study
- •Subject has a total Immuneglobulin G <7 g/L or >16 g/L at the Screening Visit
- •Subject has absolute neutrophil count <1.5x10^9/L and/or lymphocyte count <1.0x10^9/L
- •Subject has known viral hepatitis, has a positive test for Hepatitis B surface antigen or is Hepatitis C virus antibody positive
- •Subject tests positive to Human Immunodeficiency Virus (HIV) 1/2 antibodies
- •Subject has a past medical history or family history of primary immunodeficiency
- •Subject is splenectomized
- •Subject has a positive TIGRA (T cell interferon γ release assay) at the Screening Visit. If TIGRA is not available, purified protein derivative (PPD) skin test can be substituted and/or chest x-ray performed within 6 months before the Screening Visit showing no evidence of latent/active Tuberculosis (TB)
- •Subject has past (in the last 12 months ) or present substance abuse/dependence or concurrent medical conditions that in the opinion of the investigator could confound clinical study interpretation or affect the subject's ability to fully participate in the clinical study
- •Subject has a known hypersensitivity to any components of the Investigational Medicinal Product (IMP)
- •Subject has an active infection or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks before the first dose of IMP
- •Subject has 12-lead electrocardiogram (ECG) with changes considered to be clinically significant upon medical review
- •Subject has renal impairment
- •Subject has hepatic impairment
- •Subject has corrected serum calcium of >11.5 mg/dL (>2.9 mmol/L) or <8.0 mg/dL (<2.0 mmol/L) at the Screening Visit
- •Subject has active neoplastic disease or history of neoplastic disease within 5 years of entry in the clinical study
- •Subject has any other acute or chronic illness which, in the opinion of the investigator or study physician, could pose a threat or harm to the subjects
- •Subject has received a vaccination within 6 weeks before the Screening Visit or intends to have a vaccination before Day 43 of the Safety Follow-up Period
- •Subject has received any IMP or experimental procedure within 90 days before the first dose of IMP
- •Subject requires a treatment other than Paracetamol during the clinical study
- •Subject is a vulnerable subject (e.g. subject kept in detention) (Declaration of Helsinki, 1996)
结局指标
主要结局
Incidence of adverse events during the study
时间窗: Day -1 up to Day 85
次要结局
- Time to reach Cmax (Tmax)(Predose (Day 1) up to Day 85)
- Total Immunoglobulin G (IgG ) concentrations(Predose (Day 1) up to Day 85)
- Immunoglobulin G1 subclass concentrations(Predose (Day 1) up to Day 85)
- Immunoglobulin G2 subclass concentrations(Predose (Day 1) up to Day 85)
- Maximum plasma concentration (Cmax)(Predose (Day 1) up to Day 85)
- Immunoglobulin G3 subclass concentrations(Predose (Day 1) up to Day 85)
- Area under the curve from 0 to infinity (AUC)(Predose (Day 1) up to Day 85)
- Area under the curve from time 0 to time t, the time of last quantifiable concentration [AUC(0-t)](Predose (Day 1) up to Day 85)
- Immunoglobulin G4 subclass concentrations(Predose (Day 1) up to Day 85)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male SubjectsHealthy Male VolunteersNCT03464227UCB Biopharma S.P.R.L.52
已完成
1 期
A First-In-Human Study With a Single Dose UCB4019 in Healthy VolunteersHealthy VolunteersNCT02873767UCB Biopharma S.P.R.L.32
已完成
1 期
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic SubjectPsoriasisNCT02303509UCB Pharma57
已完成
1 期
A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy VolunteersHealthy VolunteersNCT02879877UCB Biopharma S.P.R.L.78
终止
1 期
A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy ParticipantsNCT06555601UCB Biopharma SRL56